GlassScriptPhysician profile
Michael G Mccusker
NPI 1043605975
$1,171.39
in general payments reported to CMS, 2019-2025
21 companies · $82.32 in 2025
The $82.32 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2021: $12.76 · 2022: $201 · 2023: $436 · 2024: $58.65 · 2025: $82.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $289.48 | 2019-2023 | Kyprolis |
| Astrazeneca Pharmaceuticals LP | $121.75 | 2023-2024 | Calquence |
| Lilly USA, LLC | $120.50 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.82 | 2019 | |
| Incyte Corporation | $79.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.48 | 2022-2023 | Opdivo |
| Daiichi Sankyo INC. | $45.27 | 2022-2024 | Enhertu |
| Beigene USA, INC. | $42.77 | 2022-2023 | Brukinsa |
| Eisai INC. | $37.92 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $34.64 | 2023 | Imbruvica |
| Sobi, INC | $31.87 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.47 | 2023 | Alunbrig |
| Novartis Pharmaceuticals Corporation | $24.29 | 2025 | |
| Emd Serono, INC. | $21.35 | 2025 | |
| Merck Sharp & Dohme LLC | $20.45 | 2025 | Keytruda Qlex, Keytruda |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $19.85 | 2022 | |
| Celgene Corporation | $18.30 | 2022 | |
| Mirati Therapeutics, INC. | $17.91 | 2023 | Krazati |
| Sumitomo Pharma America, INC. | $17.29 | 2023 | Orgovyx |
| Pfizer INC. | $16.23 | 2025 | |
| Medtronic, INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mccusker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.